title: [Antibiotic therapy of cystic fibrosis in children].
abstract: It is postulated that P. aeruginosa in monoculture or in association with Staphylococcus aureus keeps its leading position in chronic bacterial inflammatory broncho-pulmonary processes in children with cystic fibrosis. Antibiotic resistant strains of Burkholderia cepacia, Stenotrophomonas maltophila, Alcaligenes xylosoxidans were revealed (7.1% of the strains). P. aeruginosa strains were susceptible to aminoglycosides, ciprofloxacin, and polymixin B. Susceptibility of smooth and mucoid forms of P. aeruginosa to ceftazidime stayed at the level of 49.6-57.1%. Such microbial associations as P. aeruginosa sm. + S. aureus, P. aeruginosa sm. + P. aeruginosa muc. + S. aureus were mainly susceptible to ciprofloxacin, aminoglycosides and resistant to ceftasidime. Meropenem, cefepim and ciprofloxacin are highly effective antibiotics for the treatment of broncho-pulmonary processes exacerbations at children with chronic P. aeruginosa cystic fibrosis. Intravenous use of antibiotics out of hospital for the treatment of the children with cystic fibrosis is clinically effective, and is economically and psychologically reasonable. It should be used more widely in medical practice.
authors.affiliation: Research Clinical Department of Mucoviscidosis, Medical Genetics Research Centre, Russian Academy of Medical Sciences, Moscow.
authors.forename: N I
authors.initials: NI
authors.lastname: Kapranov
authors.forename: L A
authors.initials: LA
authors.lastname: Shabalova
authors.forename: N Iu
authors.initials: NIu
authors.lastname: Kashirskaia
authors.forename: O I
authors.initials: OI
authors.lastname: SimonovaO
authors.forename: A Iu
authors.initials: AIu
authors.lastname: Voronkova
authors.forename: I A
authors.initials: IA
authors.lastname: Osipova
authors.forename: S Iu
authors.initials: SIu
authors.lastname: Semykin
authors.forename: S V
authors.initials: SV
authors.lastname: Polikarpova
authors.forename: S S
authors.initials: SS
authors.lastname: Postnikov
mesh_terms: D000900:Anti-Bacterial Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D001980:Bronchi / Q000378:metabolism / Q000382:microbiology; D002648:Child; D003550:Cystic Fibrosis / Q000150:complications*; D004352:Drug Resistance, Microbial; D006801:Humans; D007262:Infusions, Intravenous; D010045:Outpatients; D011552:Pseudomonas Infections / Q000188:drug therapy / Q000382:microbiology; D011550:Pseudomonas aeruginosa / Q000187:drug effects; D012141:Respiratory Tract Infections / Q000188:drug therapy* / Q000382:microbiology / Q000517:prevention & control
chemical_list: D000900:Anti-Bacterial Agents